Close Menu

NEW YORK – AroCell today announced a collaboration and study with Boston-based Dana Faber Cancer Institute that aims to evaluate use of AroCell’s TK 210 ELISA, a quantitative immunoassay for the determination of thymidine kinase 1 (TK1) in human serum.

They will evaluate use of the assay to test samples from patients treated with palbociclib (Ibrance), a CDK4/6 inhibitor developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.